How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Published on Dec 1, 2017in Diabetes Care16.019
· DOI :10.2337/DC17-1096
Silvio E. Inzucchi97
Estimated H-index: 97
(Yale University),
Bernard Zinman42
Estimated H-index: 42
(Lunenfeld-Tanenbaum Research Institute)
+ 10 AuthorsJohn M. Lachin99
Estimated H-index: 99
(GW: George Washington University)
Sources
Abstract
OBJECTIVE In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA 1c . In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Figures & Tables
Download
📖 Papers frequently viewed together
5,361 Citations
3,149 Citations
201960.39The Lancet
1,018 Citations
References32
Newest
#1Ele FerranniniH-Index: 110
#2Simona Baldi (UniPi: University of Pisa)H-Index: 32
Last. Elza Muscelli (UniPi: University of Pisa)H-Index: 33
view all 7 authors...
OBJECTIVE Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release, including decrements in plasma glucose and insulin levels, increments in glucagon release, enhanced lipolysis, and stimulation of ketogenesis, resulting in an increase in ketonemia. We aimed at assessing the renal response to these changes. RESEARCH DESIGN AND METHODS We measured fasting and postmeal urinary excretion of glucose, β-hydroxybutyrate (β-HB), lactate, and sodium in 6...
75 CitationsSource
#1Antonius Baartscheer (UvA: University of Amsterdam)H-Index: 26
#2Cees A. Schumacher (UvA: University of Amsterdam)H-Index: 28
Last. Coert J. Zuurbier (UvA: University of Amsterdam)H-Index: 32
view all 7 authors...
Aims/hypothesis Empagliflozin (EMPA), an inhibitor of the renal sodium–glucose cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 diabetes. The underlying mechanism of this effect is unknown. Elevated cardiac cytoplasmic Na+ ([Na+]c) and Ca2+ ([Ca2+]c) concentrations and decreased mitochondrial Ca2+ concentration ([Ca2+]m) are drivers of heart failure and cardiac death. We therefore hypothesised that EMPA would directly modify [Na+]c, [Ca2+]c and [Ca2+]m in ...
258 CitationsSource
#1Pfarr EgonH-Index: 1
#2Zinman BernardH-Index: 1
Last. Wanner ChristophH-Index: 1
view all 8 authors...
1 Citations
#1Nikolaus MarxH-Index: 5
#1Nikolaus MarxH-Index: 55
Last. Darren K. McGuire (UTSW: University of Texas Southwestern Medical Center)H-Index: 91
view all 2 authors...
Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk for cardiovascular (CV) events. Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little to no impact on reducing CV risk, especially in patients with a long duration of T2D and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel class of anti-hyperglycaemic medication...
119 CitationsSource
#1Tim HeiseH-Index: 62
#2Jens Jordan (MHH: Hannover Medical School)
Last. Uli C. Broedl (Boehringer Ingelheim)H-Index: 46
view all 9 authors...
Abstract Purpose Our aim was to investigate the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on urinary and serum glucose and electrolytes, urinary volume, osmolality, and the renin−angiotensin system in patients with type 2 diabetes. Methods In an open-label study, 22 patients receiving metformin (median age 56 years; range 40–65 years) received empagliflozin 25 mg once daily for 5 days. Food, fluid, and sodium intake were standardized for 3 days before and during treat...
50 CitationsSource
#2Bruce A. Perkins (U of T: University of Toronto)H-Index: 63
Last. David Z.I. Cherney (U of T: University of Toronto)H-Index: 45
view all 5 authors...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric...
550 CitationsSource
#1Francesco Giorgino (University of Bari)H-Index: 61
#2Philip Home (Newcastle University)H-Index: 73
Last. Jaakko TuomilehtoH-Index: 217
view all 3 authors...
The overall impact of glucose lowering on vascular complications and major clinical outcomes, including mortality, in type 2 diabetes is still an open issue. While intensive glucose control has undoubted benefit for microvascular end points, the relationship between glucose-lowering approaches and reduced incidence and/or progression of macrovascular complications is less clear. This review article will discuss the effect of glucose lowering per se as well as the effects of specific glucose-lowe...
34 CitationsSource
#1Sunder Mudaliar (UCSD: University of California, San Diego)H-Index: 65
#2Sindura Alloju (UCSD: University of California, San Diego)H-Index: 1
Last. Robert R. Henry (UCSD: University of California, San Diego)H-Index: 97
view all 3 authors...
Type 2 diabetes mellitus causes excessive morbidity and premature cardiovascular (CV) mortality. Although tight glycemic control improves microvascular complications, its effects on macrovascular complications are unclear. The recent publication of the EMPA-REG OUTCOME study documenting impressive benefits with empagliflozin (a sodium–glucose cotransporter 2 [SGLT2] inhibitor) on CV and all-cause mortality and hospitalization for heart failure without any effects on classic atherothrombotic even...
343 CitationsSource
#1Cecilia C. Low WangH-Index: 12
#2Connie N. HessH-Index: 21
Last. Allison B. Goldfine (University of Colorado Denver)H-Index: 1
view all 4 authors...
Cardiovascular disease remains the principal cause of death and disability among patients with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not adequately modulated by therapeutic strategies focusing solely on optimal glycemic control with currently available drugs or approaches. In the setting of multifactorial risk reduction with statins and other lipid-lowering agents, antihypertensive therapies, ...
431 CitationsSource
#1Christoph Wanner (Yale University)H-Index: 19
#1Christoph Wanner (Yale University)H-Index: 1
Last. Bernard Zinman (Yale University)H-Index: 8
view all 10 authors...
BackgroundDiabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events. We wanted to determine the long-term renal effects of empagliflozin, an analysis that was a prespecified component of the secondary microvascular outcome of that trial. MethodsWe randomly assi...
1,757 CitationsSource
Cited By305
Newest
#1Minyoung OhH-Index: 11
#2Joon Ho ChoiH-Index: 3
Last. Cheol Whan Lee (UOU: University of Ulsan)H-Index: 76
view all 8 authors...
Source
#1Vasiliki Tsampasian (Norwich University)
#2Ranu Baral (Norwich University)
Last. Vassilios S. Vassiliou (UEA: University of East Anglia)H-Index: 15
view all 0 authors...
Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the available evidence for the use of these agents in patients with heart failure (HF) regardless of their baseline diabetes status. Methods and Results. PubMed, Web of Science, and Cochrane library databases...
Source
#1Fabie Oguz (UCL: Université catholique de Louvain)
#2Nathalie Demoulin (UCL: Université catholique de Louvain)H-Index: 15
Last. Johann Morelle (UCL: Université catholique de Louvain)H-Index: 15
view all 0 authors...
Chronic kidney disease (CKD) is a major public health problem, increasing the risk of cardiovascular events and death and potentially leading to kidney failure. Novel drugs that slow the progression of this non-communicable disease are therefore urgently needed. Initially developed as glucose-lowering drugs, inhibitors of the sodium-glucose cotransporter 2 (SGLT2) drastically reduce the overall mortality and cardiovascular events and slow the progression of CKD. Kidney protection conferred by SG...
Source
#1Ikuro MatsubaH-Index: 16
#2Masahiro TakihataH-Index: 7
Last. Takehiro KawataH-Index: 11
view all 22 authors...
Aim null Long-term changes in body composition associated with SGLT2 inhibitors have not been characterized. null Materials and methods null In this multicenter, single-arm, open-label study, 107 subjects with type 2 diabetes were treated, as add-on therapy, with canagliflozin at 100 mg for 12 months. Body composition was measured with a body composition analyzer (T-SCAN PLUS) via the impedance method to prospectively analyze changes in body components, including percentage of body fat, body fat...
Source
#1Maximilian Trum (University Hospital Regensburg)H-Index: 4
#2Johannes Riechel (University Hospital Regensburg)H-Index: 1
Last. Stefan Wagner (University Hospital Regensburg)H-Index: 24
view all 3 authors...
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the wistfully awaited results of two clinical trials (DELIVER and EMPEROR-Preserved)—may be the first drug class to improve cardiovascular outcomes in patients suffering from heart failure with preserved ejection fraction (HFpEF). Proposed mechanisms of action of this class of drugs are diverse and include metabolic and hemodynamic...
Source
#1Stephan JacobH-Index: 2
#2Andrew J. Krentz (University of Reading)H-Index: 19
Last. Lars Rydén (Karolinska University Hospital)H-Index: 88
view all 4 authors...
For many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of dugs developed as "glucose-lowering agents," SGLT2 inhibitors and GLP-1 receptor agonists, can reduce macrovascular and renal complications. These studies have prompted debate about the main aim of type 2 diabetes management. In this review, three eras of diabetes management are...
Source
#1Petter Bjornstad (Anschutz Medical Campus)H-Index: 25
#2Peter J. Greasley (AstraZeneca)H-Index: 21
Last. Daniël H. van Raalte (UvA: University of Amsterdam)H-Index: 16
view all 7 authors...
Concomitant type 2 diabetes and chronic kidney disease (CKD) increases the risk of heart failure (HF). Recent STUDIES: demonstrate beneficial effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on CKD progression and HF hospitalization in patients with and without diabetes. In addition to inhibiting glucose reabsorption, SGLT2i reduce proximal tubular sodium reabsorption, possibly leading to transient natriuresis. We review the hypothesis that SGLT2i's natriuretic and osmotic diuretic ...
Source
#2Francesca Porcellati (University of Perugia)H-Index: 26
Last. Sandro GentileH-Index: 21
view all 7 authors...
Obstructive sleep apnoea (OSA) is characterized by frequent apnoea episodes during sleep due to upper airway obstruction. The present review summarizes current knowledge on inter-relationships between OSA and type 2 diabetes mellitus (T2DM) and suggests the former as a possible target for sodium-glucose co-transporter-2 inhibitors (SGLT-2i). Based on pathophysiological mechanisms underlying OSA onset and renal SGLT-2 effects, we suggest that SGLT-2i indications might expand beyond current ones, ...
Source
#1Jose S Aguilar-Gallardo (ISMMS: Icahn School of Medicine at Mount Sinai)
#2Ashish Correa (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last. Johanna Contreras (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 10
view all 3 authors...
The heart and the kidneys are closely interconnected, and disease in one organ system can lead to disease in the other. This interdependence is illustrated in heart failure with reduced ejection fraction (HFrEF), where worsening heart failure can lead to renal dysfunction and vice versa. Further complicating this situation is the fact that drugs that serve as guideline directed medical therapy (GDMT) for HFrEF can affect renal function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a ne...
Source
#1Roy Rasalam (JCU: James Cook University)H-Index: 5
#2John Atherton (Royal Brisbane and Women's Hospital)H-Index: 82
Last. Andrew Sindone (USYD: University of Sydney)H-Index: 12
view all 6 authors...
Aims null To systematically review randomized controlled trials assessing effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on hospitalization for heart failure (HHF) and cardiac structure/function and explore randomized controlled trial (RCT)-derived evidence for SGLT2i efficacy mechanisms in heart failure (HF). null Methods and results null Systematic searches of Medline and Embase were performed. In seven trials [3730-17 160 patients; low risk of bias (RoB)], SGLT2is significantl...
Source